SEARCH

SEARCH BY CITATION

References

  • 1
    Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 82532.
  • 2
    Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 6715.
  • 3
    Lee CM, Lu SN, Changchien CS, et al. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer 1999; 86: 114350.
  • 4
    Lin R, Liddle C, Byth K, Farrell GC. Virus and host factors are both important determinants of response to interferon treatment among patients with chronic hepatitis C. J Viral Hepat 1996; 3: 8596.
  • 5
    Pagliaro L, Craxi A, Cammaa C, et al. Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology 1994; 19: 8208.
  • 6
    Hung CH, Lee CM, Lu SN, et al. Is delayed normalization of alanine aminotransferase a poor prognostic predictor in chronic hepatitis C patients treated with a combined interferon and ribavirin therapy? J Gastroenterol Hepatol 2002; 17: 130711.
  • 7
    Shiratori Y, Kato N, Yokosuka O, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology 1997; 113: 55866.
  • 8
    Hung CH, Lee CM, Lu SN, et al. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J Viral Hepat 2006; 13: 40914.
  • 9
    Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an “a 1a carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology 2000; 31: 2118.
  • 10
    Lee CM, Kee KM, Hung CH, et al. Hepatic interferon receptor mRNA expression: clinical relevance and its relationship with effectiveness of interferon plus ribavirin therapy in patients with genotype 1b hepatitis C virus infection. Antivir Ther 2006; 11: 1723.
  • 11
    Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C. Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann Intern Med 1995; 122: 1618.
  • 12
    McOmish F, Yap PL, Dow BC, et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 1994; 32: 88492.
  • 13
    Kao JH, Chen PJ, Lai MY, et al. Genotypes of hepatitis C virus in Taiwan and the progression of liver disease. J Clin Gastroenterol 1995; 21: 2337.
  • 14
    Lee CM, Lu SN, Hung CH, et al. Hepatitis C virus genotypes in southern Taiwan: prevalence and clinical implications. Trans R Soc Trop Med Hyg 2006; 100: 76774.
  • 15
    Martinot-Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 10506.
  • 16
    Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 77889.
  • 17
    Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 95865.
  • 18
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 97582.
  • 19
    Cornberg M, Wedemeyer H, Manns MP. Treatment of chronic hepatitis C with pegylated interferon and ribavirin. Curr Gastroenterol Rep 2002; 4: 2330.
  • 20
    Enomoto N, Sakuma I, Asahina Y, et al. Comparison of full-length sequences of interferon sensitive and resistant hepatitis C virus 1b: sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995; 96: 22430.
  • 21
    Gale M Jr, Blakely CM, Kwieciszewski B, et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 1998; 18: 520818.
  • 22
    Duverlie G, Khorsi H, Castelain S, et al. Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. J Gen Virol 1998; 79: 137381.
  • 23
    Zeuzem S, Lee JH, Roth WK. Mutations in the nonstructural 5A gene of European hepatitis C virus and response to interferon alfa. Hepatology 1997; 25: 7404.
  • 24
    Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 7781.
  • 25
    Khorsi H, Castelain S, Wyseur A, et al. Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients. J Hepatol 1997; 27: 727.
  • 26
    Squadrito G, Orlando ME, Cacciola I, et al. Long-term response to interferon alpha is unrelated to “interferon sensitivity determining region” variability in patients with chronic hepatitis C virus-1b infection. J Hepatol 1999; 30: 10237.
  • 27
    Yoshioka K, Kobayashi M, Orito E, et al. Biochemical response to interferon therapy correlates with interferon sensitivity-determining region in hepatitis C virus genotype 1b infection. J Viral Hepat 2001; 8: 4219.
  • 28
    Watanabe H, Enomoto N, Nagayama K, et al. Number and position of mutations in the interferon (IFN) sensitivity-determining region of the gene for nonstructural protein 5A correlate with IFN efficacy in hepatitis C virus genotype 1b infection. J Infect Dis 2001; 183: 1195203.
  • 29
    Hofgartner WT, Polyak SJ, Sullivan DG, Carithers RL Jr, Gretch DR. Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b. J Med Virol 1997; 53: 11826.
  • 30
    Kurosaki M, Enomoto N, Murakami T, et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology 1997; 25: 7503.
  • 31
    Murashima S, Ide T, Miyajima I, et al. Mutations in the NS5A gene predict response to interferon therapy in Japanese patients with chronic hepatitis C and cirrhosis. Scand J Infect Dis 1999; 31: 2732.
  • 32
    Witherell GW, Beineke P. Statistical analysis of combined substitution in nonstructural 5A region of hepatitis C virus and interferon response. J Med Virol 2001; 62: 816.
  • 33
    Reddy KR, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 4338.
  • 34
    Chambers TJ, Fan X, Droll DA, et al. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. J Virol 2005; 79: 307183.
  • 35
    Strader DB, Wright T, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 114771.
  • 36
    Stuyver L, Wyseur A, Van Arnhem W, Hernandez F, Maertens G. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996; 34: 225966.
  • 37
    Lee SD, Yu ML, Cheng PN, et al. Comparison of 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat 2005; 12: 28391.
  • 38
    Yu ML, Chuang WL, Dai CY, et al. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy. Transl Res 2006; 148: 1207.
  • 39
    Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43: 95460.
  • 40
    Sarrazin C, Herrmann E, Bruch K, Zeuzem S. Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses. J Virol 2002; 76: 1107990.
  • 41
    Sarrazin C, Berg T, Lee JH, et al. Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy. J Hepatol 1999; 30: 100413.
  • 42
    Polyak SJ, Paschal DM, McArdle S, Gale MJ Jr, Moradpour D, Gretch DR. Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication. Hepatology 1999; 29: 126271.
  • 43
    Gale JM, Korth MJ, Tang NM, et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997; 230: 21727.
  • 44
    Polyak SJ, Khabar KS, Paschal DM, et al. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol 2001; 75: 6095106.
  • 45
    Hung CH, Lee CM, Lu SN, et al. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin. J Viral Hepat 2003; 10: 8794.
  • 46
    Paterson M, Laxton CD, Thomas HC, Ackrill AM, Foster GR. Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response. Gastroenterology 1999; 117: 118797.
  • 47
    Pawlotsky JM, Germanidis G, Neumann AU, et al. Interferon resistance of hepatitis C virus genotype 1b: relationship to non-structural 5A gene quasispecies mutations. J Virol 1998; 72: 2795805.
  • 48
    Saiz JC, Lopez-Labrador FX, Ampurdanes S, et al. The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus. J Infect Dis 1998; 177: 83947.
  • 49
    Sarrazin C, Berg T, Lee J-H, et al. Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response. J Infect Dis 2000; 181: 43241.
  • 50
    Murphy MD, Rosen HR, Marousek GI, Chou S. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection. Dig Dis Sci 2002; 47: 1195205.